Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 9 (September)

1. Exaggerated apoptosis and NF-kappaB activation in pancreatic and tracheal cystic fibrosis cells.
   FASEB J, 21(11): 2939-48. [Abstract] [Full-text]
2. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
   Clin Cancer Res, 13(17): 5144-9. [Abstract] [Full-text]
3. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
   Cancer Lett, 256(1): 25-8. [Abstract] [Full-text]
4. Chronic hypergastrinemia: causes and consequences.
   Dig Dis Sci, 52(10): 2482-9. [Abstract] [Full-text]
5. Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells.
   Dig Dis Sci, 52(10): 2646-52. [Abstract] [Full-text]
6. Preoperative endoscopic pancreatic stenting for prophylaxis of pancreatic duct disruption during extirpation of a pancreatic head tumor.
   Am J Surg, 194(4): 553-5. [Abstract] [Full-text]
7. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
   Cancer, 110(6): 1227-34. [Abstract] [Full-text]
8. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
   Cell Signal, 19(11): 2237-46. [Abstract] [Full-text]
9. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
   J Surg Res, 142(2): 281-6. [Abstract] [Full-text]
10. Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
    J Surg Res, 142(2): 378-86. [Abstract] [Full-text]
11. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology.
    Ann Surg, 246(4): 644-51; discussion 651-4. [Abstract] [Full-text]
12. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
    Cancer, 110(7): 1457-68. [Abstract] [Full-text]
13. Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
    Pancreas, 35(3): 224-31. [Abstract] [Full-text]
14. The nature of neural invasion by pancreatic cancer.
    Pancreas, 35(3): 218-23. [Abstract] [Full-text]
15. Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment.
    Pancreas, 35(3): 212-7. [Abstract] [Full-text]
16. Intranuclear rodlets in human pancreatic islet cells.
    Pancreas, 35(3): 207-11. [Abstract] [Full-text]
17. Proliferation, hyperplasia, neogenesis, and neoplasia in the islets of Langerhans.
    Pancreas, 35(3): 199-206. [Abstract] [Full-text]
18. Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer.
    Pancreas, 35(3): e9-15. [Abstract] [Full-text]
19. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
    Pancreas, 35(3): e16-26. [Abstract] [Full-text]
20. Flavonols and pancreatic cancer risk: the multiethnic cohort study.
    Am J Epidemiol, 166(8): 924-31. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.